Parametric Portfolio Associates LLC raised its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 20.3% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 174,763 shares of the company’s stock after acquiring an additional 29,484 shares during the quarter. Parametric Portfolio Associates LLC owned approximately 0.47% of Omnicell worth $7,532,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in OMCL. BlackRock Inc. increased its position in Omnicell by 139,475.2% in the 1st quarter. BlackRock Inc. now owns 4,487,343 shares of the company’s stock valued at $182,412,000 after acquiring an additional 4,484,128 shares during the period. Principal Financial Group Inc. increased its position in Omnicell by 124.9% in the 2nd quarter. Principal Financial Group Inc. now owns 660,803 shares of the company’s stock valued at $28,481,000 after acquiring an additional 367,019 shares during the period. Russell Investments Group Ltd. increased its position in Omnicell by 70.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 347,914 shares of the company’s stock valued at $14,995,000 after acquiring an additional 143,474 shares during the period. Rice Hall James & Associates LLC increased its position in Omnicell by 47.1% in the 2nd quarter. Rice Hall James & Associates LLC now owns 434,422 shares of the company’s stock valued at $18,724,000 after acquiring an additional 139,069 shares during the period. Finally, Vanguard Group Inc. increased its position in Omnicell by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 1,860,299 shares of the company’s stock valued at $75,622,000 after acquiring an additional 97,345 shares during the period.
OMCL has been the subject of several recent research reports. Dougherty & Co upped their price target on shares of Omnicell from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Friday, July 28th. Craig Hallum upped their price target on shares of Omnicell from $46.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, July 28th. Cantor Fitzgerald restated a “buy” rating and issued a $47.00 price target on shares of Omnicell in a research report on Tuesday, July 25th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Omnicell in a research note on Thursday, October 19th. Finally, Benchmark Co. upped their price objective on shares of Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, September 5th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $51.86.
ILLEGAL ACTIVITY WARNING: “Parametric Portfolio Associates LLC Has $7.53 Million Position in Omnicell, Inc. (NASDAQ:OMCL)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/27/parametric-portfolio-associates-llc-has-7-53-million-position-in-omnicell-inc-omcl.html.
In related news, EVP Robin Gene Seim sold 15,109 shares of Omnicell stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $50.86, for a total value of $768,443.74. Following the sale, the executive vice president now owns 58,144 shares in the company, valued at $2,957,203.84. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman Randall A. Lipps sold 40,000 shares of the business’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $49.76, for a total transaction of $1,990,400.00. Following the sale, the chairman now owns 196,551 shares in the company, valued at approximately $9,780,377.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 146,594 shares of company stock worth $7,369,791. 3.77% of the stock is currently owned by company insiders.
Shares of Omnicell, Inc. (OMCL) opened at 53.95 on Friday. The company’s market capitalization is $2.02 billion. The stock has a 50 day moving average of $50.92 and a 200-day moving average of $45.86. Omnicell, Inc. has a 1-year low of $30.35 and a 1-year high of $55.40.
Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Wednesday, October 25th. The company reported $0.42 earnings per share for the quarter, meeting the consensus estimate of $0.42. The business had revenue of $186.78 million for the quarter, compared to analysts’ expectations of $192.45 million. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.40 earnings per share. Analysts forecast that Omnicell, Inc. will post $1.30 earnings per share for the current year.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.